Lucid Diagnostics to Be Deconsolidated From PAVmed's Financial Statements
PAVmed Announces Efforts To Regain Nasdaq Compliance, Including Lucid Diagnostics Deconsolidation From Financials And Appointment Of Sundeep Agrawal To Board; Deconsolidation Increases PAVmed's Stockholder Equity While Retaining Largest Shareholder...
Press Release: PAVmed Announces Efforts to Regain Compliance With Nasdaq Listing Requirements
PAVmed's Strategic Overhaul to Secure Nasdaq Compliance
Express News | PAVmed Inc - Appointment of Sundeep Agrawal to Board to Replace Departing Directors
Express News | PAVmed Inc - Announces Efforts to Regain Compliance With Nasdaq Listing Requirements
Express News | PAVmed Inc - Continues to Explore All Available Alternatives for Further Increasing Co's Stockholders' Equity
Express News | PAVmed Inc - in Connection With Deconsolidation, Co Expects to Recognize Estimated Non-Cash Gain of About $70 Mln in Q3 of 2024
Express News | PAVmed Inc - Determined That Lucid Diagnostics Inc and Its Subsidiaries Will Be Deconsolidated From Co's Financial Statements as of Sept 10
Lucid Diagnostics to Host Symposium on Non-Endoscopic Esophageal Precancer Screening at the 20th International Society for Diseases of the Esophagus (ISDE) World Congress
PAVmed Is Maintained at Buy by Ascendiant Capital
Ascendiant Capital Maintains Buy on PAVmed, Lowers Price Target to $21
PAVmed Analyst Ratings
Express News | Lucid Diagnostics Signs Memorandum of Understanding With Front Line Mobile Health
Express News | Lucid Diagnostics Announces Publication of Analytical Validation Study of Esoguard® for Early Detection of Esophageal Precancer and Cancer
Maxim Group Maintains PAVmed(PAVM.US) With Buy Rating
Maxim Group analyst Anthony Vendetti maintains $PAVmed(PAVM.US)$ with a buy rating.According to TipRanks data, the analyst has a success rate of 26.7% and a total average return of -17.4% over the
Earnings Call: PAVmed Reports Growth and Strategic Moves in Q2 2024
Earnings Call Summary | PAVmed(PAVM.US) Q2 2024 Earnings Conference
Q2 2024 PAVmed Inc Earnings Call
PAVmed Inc. (PAVM) Q2 2024 Earnings Call Transcript